annual Report 2009 - STRATEC Biomedical AG

Any write-ups or write-downs recognized in the year under report in the separate financial statements on shares held
in companies included in the consolidated financial statements have to be reversed in the consolidated financial statements.
The same applies for transaction costs recognized as acquisition costs pursuant to IAS 27 in the separate financial
statements of the acquiring company. As in the previous years, no such write-ups or write-downs were undertaken
in the 2009 financial year.
Intercompany profits and losses, sales, income and expenses have been eliminated, as have receivables and liabilities
between the companies included in the consolidated financial statements.
The income tax implications of consolidation entries have been accounted for by recognizing deferred taxes.
The shares held in companies not included in the scope of consolidation have been recognized at amortized cost under
financial assets – (3) “Interests in associates”.
2. Scope of consolidation
The consolidated financial statements of STRATEC AG basically include all companies where STRATEC AG has the possibility
of determining the financial and business policy (control relationship). These companies are included for the first
time as soon as STRATEC AG gains the possibility of exercising control.
In addition to STRATEC AG, the consolidated financial statements as of December 31, 2009 include the following subsidiaries
by way of full consolidation:
• Robion AG, Neuhausen am Rheinfall, Switzerland
• Sanguin International Ltd., Burton upon Trent, UK
• Invitek Gesellschaft für Biotechnik & Biodesign mbH, Berlin, Germany
The subsidiary Robion AG was founded on February 23, 2005. The share capital of Robion AG amounts to CHF 100,000
and is divided into 100 bearer shares of CHF 1,000 each. STRATEC AG holds 100 % of the voting rights in the company.
An amount of u 65 thousand was spent in connection with the takeover of share capital as of February 23, 2005. This
amount has been translated at the exchange rate as of the acquisition date.
The subsidiary Sanguin International Ltd., including its shareholding in Sanguin International Inc., Hamden, CT, USA, was
acquired on March 13, 2006. The share capital of Sanguin International Ltd. amounts to GBP 563. STRATEC AG holds
100 % of the company’s capital. The costs of acquisition amounted to u 5,999 thousand, including u 108 thousand of
ancillary expenses directly attributable to the acquisition.
By acquiring 100 % of the shares in Invitek Gesellschaft für Biotechnik & Biodesign mbH, Berlin, (hereinafter “Invitek”)
via the group company Robion AG, STRATEC gained control of this company on April 23, 2009. The Invitek acquisition
has enabled the STRATEC Group to broaden its product range in the field of automation solutions for nucleic acid purification
applications.
The acquisition costs for the business combination amounted to u 3,297 thousand as of the acquisition date and are
structured as follows:
in v thousand
Purchase price paid 1,745
Granting of shares in STRATEC Biomedical Systems AG (70,597 shares) 1,002
Netting of receivables 320
Compensation dependent on future events 230
Total 3,297
60 stratec Annual Report 2009